SRC 家族蛋白酪氨酸激酶：结直肠癌治疗的一个新的有前途的靶点。
The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.
机构信息
Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
出版信息
Clin Colorectal Cancer. 2010 Apr;9(2):89-94. doi: 10.3816/CCC.2010.n.012.
Abstract
Aberrant activation of the Src family of tyrosine kinases has been implicated in the development and progression of colorectal cancer (CRC). As a result, Src inhibitors are now being studied as possible therapeutic agents to treat metastatic disease. In this review, we discuss the effects of aberrant Src activation in CRC, Src as a target of single-agent drug therapy, and Src as a target of combination therapy with epidermal growth factor receptor inhibition and cytotoxic chemotherapy. The greatest potential for clinically relevant benefit most likely lies in combination regimens. Further evaluation with biomarkers will continue to define the molecular phenotype of patients with CRC who will benefit the most from Src-based therapy.
摘要
Src 家族酪氨酸激酶的异常激活与结直肠癌（CRC）的发生和发展有关。因此，Src 抑制剂现正被研究作为治疗转移性疾病的潜在治疗药物。在这篇综述中，我们讨论了 Src 异常激活在 CRC 中的作用、作为单一药物治疗靶点的 Src 以及作为表皮生长因子受体抑制和细胞毒性化疗联合治疗靶点的 Src。最有可能具有临床相关性的获益的最大潜力在于联合方案。进一步的生物标志物评估将继续确定最受益于 Src 治疗的 CRC 患者的分子表型。
相似文献
1
The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.
Clin Colorectal Cancer. 2010 Apr;9(2):89-94. doi: 10.3816/CCC.2010.n.012.
2
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Cochrane Database Syst Rev. 2017 Jun 27;6(6):CD007047. doi: 10.1002/14651858.CD007047.pub2.
3
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.
Clin Cancer Res. 2017 Aug 1;23(15):4146-4154. doi: 10.1158/1078-0432.CCR-16-3138. Epub 2017 Mar 9.
4
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Second-line systemic therapy for metastatic colorectal cancer.
Cochrane Database Syst Rev. 2017 Jan 27;1(1):CD006875. doi: 10.1002/14651858.CD006875.pub3.
6
Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. doi: 10.3310/hta11120.
7
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Cancer Res. 2009 May 1;69(9):3842-9. doi: 10.1158/0008-5472.CAN-08-2246. Epub 2009 Apr 21.
8
A systematic overview of chemotherapy effects in colorectal cancer.
Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367.
9
The Src family kinase inhibitor drug Dasatinib and glucocorticoids display synergistic activity against tongue squamous cell carcinoma and reduce MET kinase activity.
Cell Commun Signal. 2025 Jun 19;23(1):293. doi: 10.1186/s12964-025-02129-8.
10
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Health Technol Assess. 2013 Apr;17(14):1-237. doi: 10.3310/hta17140.
引用本文的文献
1
Network Toxicology and Molecular Docking to Elucidate the Mechanisms of Intestinal Toxicity Induced by P-Phenylenediamine Antioxidants and Their Quinone Derivatives.
Toxics. 2025 Jun 6;13(6):480. doi: 10.3390/toxics13060480.
2
Prognostic gene biomarkers for c-Src inhibitor Si162 sensitivity in melanoma cells.
Turk J Biol. 2023 Nov 6;48(1):13-23. doi: 10.55730/1300-0152.2678. eCollection 2024.
3
Cyclooxygenase and Lipoxygenase Gene Expression in the Inflammogenesis of Colorectal Cancer: Correlated Expression of EGFR, JAK STAT and Src Genes, and a Natural Antisense Transcript, RP11-C67.2.2.
Cancers (Basel). 2023 Apr 20;15(8):2380. doi: 10.3390/cancers15082380.
4
FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC.
Theranostics. 2023 Feb 22;13(4):1401-1418. doi: 10.7150/thno.82269. eCollection 2023.
5
c-Src inhibitor PP2 inhibits head and neck cancer progression through regulation of the epithelial-mesenchymal transition.
Exp Biol Med (Maywood). 2023 Mar;248(6):492-500. doi: 10.1177/15353702221139183. Epub 2022 Dec 17.
6
Kindlin-2 promotes Src-mediated tyrosine phosphorylation of androgen receptor and contributes to breast cancer progression.
Cell Death Dis. 2022 May 20;13(5):482. doi: 10.1038/s41419-022-04945-z.
7
Reckoning apigenin and kaempferol as a potential multi-targeted inhibitor of EGFR/HER2-MEK pathway of metastatic colorectal cancer identified using rigorous computational workflow.
Mol Divers. 2022 Dec;26(6):3337-3356. doi: 10.1007/s11030-022-10396-7. Epub 2022 Feb 10.
8
Identification of a Potent Cytotoxic Pyrazole with Anti-Breast Cancer Activity That Alters Multiple Pathways.
Cells. 2022 Jan 12;11(2):254. doi: 10.3390/cells11020254.
9
Differential Impact of Severity and Duration of , Medical Countermeasures, and a Disease-Modifier, Saracatinib, on Brain Regions in the Rat Diisopropylfluorophosphate Model.
Front Cell Neurosci. 2021 Oct 15;15:772868. doi: 10.3389/fncel.2021.772868. eCollection 2021.
10
Dickkopf-2 regulates the stem cell marker LGR5 in colorectal cancer via HNF4α1.
iScience. 2021 Apr 15;24(5):102411. doi: 10.1016/j.isci.2021.102411. eCollection 2021 May 21.
本文引用的文献
1
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
Invest New Drugs. 2013 Aug;31(4):967-73. doi: 10.1007/s10637-013-9929-8. Epub 2013 Jan 30.
2
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Mol Cancer Ther. 2009 Jun;8(6):1484-93. doi: 10.1158/1535-7163.MCT-09-0075. Epub 2009 Jun 9.
3
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
Clin Cancer Res. 2009 Jun 15;15(12):4138-46. doi: 10.1158/1078-0432.CCR-08-3021. Epub 2009 Jun 9.
4
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.
J Clin Oncol. 2009 Aug 1;27(22):3677-83. doi: 10.1200/JCO.2008.20.5278. Epub 2009 May 26.
5
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Cancer Res. 2009 May 1;69(9):3842-9. doi: 10.1158/0008-5472.CAN-08-2246. Epub 2009 Apr 21.
6
Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic.
Gastrointest Cancer Res. 2007;1(4 Suppl 2):S37-41.
7
Src-Induced cisplatin resistance mediated by cell-to-cell communication.
Cancer Res. 2009 Apr 15;69(8):3619-24. doi: 10.1158/0008-5472.CAN-08-0985. Epub 2009 Apr 7.
8
Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
Cancer Biol Ther. 2009 Apr;8(8):696-703. doi: 10.4161/cbt.8.8.7903. Epub 2009 Apr 22.
9
Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
Cancer Res. 2009 Mar 1;69(5):1958-65. doi: 10.1158/0008-5472.CAN-08-2944. Epub 2009 Feb 17.
10
Caveolin-1 in tumor progression: the good, the bad and the ugly.
Cancer Metastasis Rev. 2008 Dec;27(4):715-35. doi: 10.1007/s10555-008-9160-9.
Zotero 插件